Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ranirestat effective and orally active aldose reductase inhibitor ( IC50s: 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively and a Ki: 0.38 nM for recombinant human AR). Ranirestat has a neuroprotective effect on diabetic retinas.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,330 | 5日内发货 | ||
5 mg | ¥ 2,250 | 5日内发货 | ||
25 mg | ¥ 7,690 | 8-10周 | ||
50 mg | ¥ 9,990 | 8-10周 | ||
100 mg | ¥ 15,400 | 8-10周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,720 | 5日内发货 |
产品描述 | Ranirestat effective and orally active aldose reductase inhibitor ( IC50s: 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively and a Ki: 0.38 nM for recombinant human AR). Ranirestat has a neuroprotective effect on diabetic retinas. |
靶点活性 | Aldose reductase (rat lens):11 nM, Aldose reductase (human recombinant):(ki)0.38 nM, Aldose reductase (human recombinant):15 nM |
体外活性 | The potency of Ranirestat inhibition of sorbitol accumulation is similar between rat erythrocytes and sciatic nerves (IC50: 0.010 μM and 0.041 μM, respectively). Ranirestat concentration-dependently inhibits sorbitol accumulation in rat erythrocytes and sciatic nerves incubated in the high concentration (500 mg/dl) of glucose [1]. |
体内活性 | Ranirestat also improves the STZ-induced decrease in motor nerve conduction velocity (MNCV) in a dose-dependent manner. Ranirestat (0.03-1.0 mg/kg;p.o.; once daily; for 3 weeks; male STD-Wistar rats) treatment dose-dependently reduces the elevated sorbitol and fructose levels in the rat sciatic nerves without affecting blood glucose level [1]. |
别名 | AS-3201 |
分子量 | 420.19 |
分子式 | C17H11BrFN3O4 |
CAS No. | 147254-64-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (118.99 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3799 mL | 11.8994 mL | 23.7988 mL | 59.4969 mL |
5 mM | 0.476 mL | 2.3799 mL | 4.7598 mL | 11.8994 mL | |
10 mM | 0.238 mL | 1.1899 mL | 2.3799 mL | 5.9497 mL | |
20 mM | 0.119 mL | 0.595 mL | 1.1899 mL | 2.9748 mL | |
50 mM | 0.0476 mL | 0.238 mL | 0.476 mL | 1.1899 mL | |
100 mM | 0.0238 mL | 0.119 mL | 0.238 mL | 0.595 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ranirestat 147254-64-6 Others AS 3201 AS-3201 AS3201 Inhibitor inhibitor inhibit